C4 Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
C4 Therapeutics, Inc. (CCCC) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 652.22 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Shareholders' Equity
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-08-11
- C4 Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-06-30 was 575.44K shares, a 88.55% increase year-over-year.
- C4 Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-03-31 was 76.78K shares, a 95.89% decline year-over-year.
- C4 Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 0.00 shares, a 100.00% decline year-over-year.
- C4 Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-06-30 was 305.19K shares, a 43.99% decline year-over-year.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month |
|---|---|---|---|
| 2026-06-30 | 575.44K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | 652.22K shares 10-Q · filed 2026-08-11 | |
| 2026-03-31 | 76.78K shares 10-Q · filed 2026-05-12 | ||
| 2025-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | 305.19K shares derived: sum of 2 quarters · filed 2025-11-06 | 2.17M shares 10-Q · filed 2025-11-06 |
| 2025-06-30 | 305.19K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | 2.17M shares 10-Q · filed 2025-08-07 | |
| 2025-03-31 | 1.87M shares 10-Q · filed 2025-05-07 | ||
| 2024-09-30 | 327.16K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | 872.08K shares derived: sum of 2 quarters · filed 2024-10-31 | 3.38M shares 10-Q · filed 2024-10-31 |
| 2024-06-30 | 544.92K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | 3.06M shares 10-Q · filed 2024-08-01 | |
| 2024-03-31 | 2.51M shares 10-Q · filed 2024-05-08 | ||
| 2023-09-30 | 2.30M shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-01 | 2.54M shares derived: sum of 2 quarters · filed 2023-11-01 | 4.43M shares 10-Q · filed 2023-11-01 |
| 2023-06-30 | 236.63K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | 2.13M shares 10-Q · filed 2023-08-08 | |
| 2023-03-31 | 1.89M shares 10-Q · filed 2023-05-04 | ||
| 2021-09-30 | 228.40K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | 628.25K shares derived: sum of 2 quarters · filed 2021-11-10 | 1.63M shares 10-Q · filed 2021-11-10 |
| 2021-06-30 | 399.85K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-11 | 1.40M shares 10-Q · filed 2021-08-11 | |
| 2021-03-31 | 1.00M shares 10-Q · filed 2021-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |